John Isham founded RadiaDyne® in 2007 and is responsible for establishing RadiaDyne’s brand in the radiation oncology space, developing a robust and differentiated IP portfolio while delivering five FDA cleared class II medical devices to market. John’s career in the medical device industry spans 17 years and includes a remarkable track record of results in sales, executive management, R&D, Product Development and business leadership within early stage and mid-cap medical device companies. In addition, John has earned multiple patents and patents pending. He earned his B.B.A. with a focus in marketing from Texas Tech University. John is proud to actively support many Veterans and child advocacy charity's core missions.
Bret Boudousquie joined RadiaDyne® in July 2015 and is responsible for general management and commercial operations of RadiaDyne. Bret has been instrumental in developing RadiaDyne’s commercial team, systems and processes for scale up. Bret’s career in the medical device industry spans 19 years and includes a track record of exceptional results in sales, training, professional education, marketing and sales management in early stage growth companies and Johnson & Johnson. His focus prior to RadiaDyne has been surgical and implantable medical devices for orthopedics, spine and general surgery. He earned his B.S. in Business Administration, with a concentration in Finance, from the University of North Carolina at Wilmington.
Steve Gelmine joined RadiaDyne® in October 2015. His responsibilities include product launch, sales and sales training, professional education and marketing of the game changing OARtrac dosimetry platform. Steve’s leadership has been instrumental in driving RadiaDyne’s business growth since joining the company. Steve’s track record of exceptional performance in the medical device industry spans 26 years with progressive responsibility including sales, sales planning, sales training, professional education, product marketing, research and development, and executive sales management, primarily with the surgical device division of Johnson & Johnson. He earned his B.S. in Pre Law-Criminology, from Florida State University, where he was a 4 year varsity letterman in baseball. Mr. Gelmine was twice drafted in the Major League baseball draft; by the Cleveland Indians out of High School and the Houston Astros after college where he played professional baseball.
Rick Randall joined the RadiaDyne Leadership Team in August 2017, to provide guidance to the executive team and board as RadiaDyne transitions to a medical device & diagnostics company with great potential for rapid growth with the recent launch of the OARtrac platform. Rick has spent the majority of his career managing, directing and founding early stage medical device companies that have enabled many significant medical procedures over the past three decades. Rick has broad experience as a CEO, Chairman and Director of a number of emerging medical device firms. Businesses under Rick’s leadership have achieved $1.5 billion in value creation from IPOs or mergers and acquisitions.
Rick has led entrepreneurial companies servicing the cardiovascular, neurovascular, orthopedic, spine and gastroenterology fields. Rick has co-founded three medical device companies and has served a role in numerous corporate financings and M&A transactions. Rick has extensive experience in early-stage medical device general management, marketing, financing, manufacturing, R&D, regulatory, reimbursement and international and domestic product sales.
From 1989 to 1993 Rick was President and CEO of Target Therapeutics, Inc., the pioneer and leader in the emerging field of interventional neurosurgery. Rick led Target through several global product launches and the invention and development of its revolutionary endovascular coil technology for the minimally invasive treatment of life-threatening cerebral aneurysms. During Rick’s tenure Target achieved profitability and he managed the IPO. Rick remained a Director on the Board of Target through the sale of the company to Boston Scientific Corp in 1997. As CEO of Target Therapeutics, Rick was a co-founder of corporate spin-offs including Cardima, Conceptus and Prograft.
From 1993 to 2000, Rick served as President and CEO of Innovasive Devices, Inc., a developer and marketer of innovative arthroscopic surgery products. Product sales grew to $17 million during his tenure. He joined Innovasive as a pre-revenue, venture-funded start-up and led it through a private equity financing, initial product development, numerous product launches, an acquisition of a private product development firm (Medicine Lodge), IPO and eventual sale of the company to the Ethicon Division of Johnson and Johnson, Inc.
From 2002 to 2011, Rick was Chairman, President and CEO of TranS1, Inc., a pioneer in the minimally invasive spine surgery field. He joined the firm as the first employee and managed the company through early product development, product regulatory approvals, market launches in US and Europe, two private equity financings and an Initial Public Offering. Revenues from product sales grew to $30 million during his tenure as CEO.
From 2011 to 2103, while with Montreux Equity Venture Partners, Mr. Randall was appointed CEO and Chairman of Avantis Medical, a venture-backed firm focused on gastrointestinal imaging. From 2013 through 2014, Rick was CEO of Medical Compression Systems, an Israel-based company serving the post-surgical Deep Vein Thrombosis prevention market. From 2014 to 2017 Rick was CEO of Omni Life Sciences, who developed and markets the first Robotic Assisted Total Knee Replacement Surgery System in the United States.